Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Rating of “Moderate Buy” from Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has been given an average recommendation of “Moderate Buy” by the four ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $37.50.

Several brokerages recently issued reports on INTS. Weiss Ratings lowered Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Freedom Capital upgraded Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. Finally, Wall Street Zen upgraded Intensity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th.

Hedge Funds Weigh In On Intensity Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Intensity Therapeutics in the fourth quarter valued at approximately $26,000. Corient Private Wealth LLC purchased a new stake in shares of Intensity Therapeutics in the fourth quarter valued at about $41,000. State Street Corp increased its stake in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the last quarter. Legacy Advisors LLC acquired a new stake in Intensity Therapeutics during the fourth quarter worth $63,000. Finally, Mesirow Financial Investment Management Inc. increased its stake in Intensity Therapeutics by 81.8% during the third quarter. Mesirow Financial Investment Management Inc. now owns 200,000 shares of the company’s stock worth $49,000 after acquiring an additional 90,000 shares during the last quarter. Hedge funds and other institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Trading Down 0.4%

Shares of NASDAQ INTS opened at $5.19 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.92 and a quick ratio of 5.92. The stock has a market capitalization of $13.18 million, a P/E ratio of -0.33 and a beta of 2.95. Intensity Therapeutics has a 1-year low of $4.63 and a 1-year high of $43.50. The business has a fifty day moving average price of $6.17 and a 200 day moving average price of $8.73.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Friday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter. Equities research analysts expect that Intensity Therapeutics will post -4.61 EPS for the current fiscal year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.